Novavax (NVAX)
(Delayed Data from NSDQ)
$3.95 USD
-0.20 (-4.82%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $3.96 +0.01 (0.25%) 7:18 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for Novavax, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 579 | 1,347 | 1,527 | 805 | 82 |
Receivables | 297 | 82 | 455 | 262 | 8 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 42 | 37 | 0 | 0 | 0 |
Other Current Assets | 226 | 237 | 174 | 181 | 8 |
Total Current Assets | 1,144 | 1,703 | 2,155 | 1,248 | 97 |
Net Property & Equipment | 306 | 294 | 229 | 180 | 11 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 127 | 126 | 136 | 141 | 57 |
Deposits & Other Assets | 35 | 28 | 57 | 13 | 8 |
Total Assets | 1,797 | 2,259 | 2,577 | 1,582 | 173 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 325 | 0 | 0 | 0 |
Accounts Payable | 133 | 217 | 127 | 54 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 5 | 27 | 131 | 106 | 0 |
Accrued Expenses | 395 | 591 | 674 | 142 | 20 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1,103 | 1,300 | 1,459 | 277 | 3 |
Total Current Liabilities | 1,635 | 2,460 | 2,390 | 580 | 26 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 622 | 179 | 173 | 0 | 3 |
Convertible Debt | 168 | 166 | 323 | 322 | 321 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 56 | 31 | 0 | 40 | 0 |
Other Non-Current Liabilities | 33 | 56 | 42 | 13 | 10 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2,514 | 2,893 | 2,928 | 955 | 359 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 0 |
Capital Surplus | 4,192 | 3,738 | 3,352 | 2,535 | 1,261 |
Retained Earnings | -4,821 | -4,276 | -3,618 | -1,874 | -1,432 |
Other Equity | 3 | -6 | -1 | 7 | -13 |
Treasury Stock | 92 | 91 | 85 | 42 | 3 |
Total Shareholder's Equity | -717 | -634 | -352 | 627 | -186 |
Total Liabilities & Shareholder's Equity | 1,797 | 2,259 | 2,577 | 1,582 | 173 |
Total Common Equity | -717 | -634 | -352 | 627 | -186 |
Shares Outstanding | 118.70 | 78.50 | 75.60 | 63.60 | 32.30 |
Book Value Per Share | -6.04 | -8.08 | -4.65 | 9.86 | -5.76 |
Fiscal Year End for Novavax, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 579 | 662 | 516 | 635 |
Receivables | NA | 297 | 124 | 395 | 113 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 42 | 70 | 23 | 34 |
Other Current Assets | NA | 226 | 152 | 193 | 189 |
Total Current Assets | NA | 1,144 | 1,007 | 1,128 | 971 |
Net Property & Equipment | NA | 306 | 301 | 300 | 307 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 127 | 124 | 128 | 130 |
Deposits & Other Assets | NA | 35 | 35 | 33 | 31 |
Total Assets | NA | 1,797 | 1,657 | 1,685 | 1,543 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 133 | 102 | 87 | 125 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 5 | 1 | 1 | 1 |
Accrued Expenses | NA | 395 | 311 | 458 | 519 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1,103 | 1,054 | 1,050 | 1,274 |
Total Current Liabilities | NA | 1,635 | 1,469 | 1,596 | 1,919 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 622 | 609 | 607 | 274 |
Convertible Debt | NA | 168 | 168 | 167 | 167 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 56 | 53 | 31 | 31 |
Other Non-Current Liabilities | NA | 37 | 38 | 48 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 2,514 | 2,336 | 2,440 | 2,438 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1 | 1 | 1 | 1 |
Capital Surplus | NA | 4,192 | 4,067 | 3,856 | 3,768 |
Retained Earnings | NA | -4,821 | -4,643 | -4,512 | -4,570 |
Other Equity | NA | 3 | -12 | -8 | -3 |
Treasury Stock | NA | 92 | 92 | 91 | 91 |
Total Shareholder's Equity | NA | -717 | -678 | -755 | -896 |
Total Liabilities & Shareholder's Equity | NA | 1,797 | 1,657 | 1,685 | 1,543 |
Total Common Equity | 0 | -717 | -678 | -755 | -896 |
Shares Outstanding | 139.90 | 118.70 | 118.70 | 86.30 | 86.30 |
Book Value Per Share | 0.00 | -6.04 | -5.71 | -8.74 | -10.38 |